• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Virgin Galactic Are Trading Lower By Around 18%; Here Are 20 Stocks Moving Premarket

    6/23/23 8:14:21 AM ET
    $AGLE
    $BDRX
    $BENF
    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AGLE alert in real time by email

    Gainers

    • Castellum, Inc. (NYSE:CTM) shares surged 176.6% to $1.25 in pre-market trading after dropping around 6% on Thursday.
    • OncoSec Medical Incorporated (NASDAQ:ONCS) shares gained 99.9% to $0.4201 in pre-market trading after gaining around 8% on Thursday.
    • Conformis, Inc. (NASDAQ:CFMS) shares rose 91.4% to $2.22 in pre-market trading after the company agreed to be acquired by restor3d, a leading personalized 3D-printed orthopedic company, for a purchase price of $2.27 per share in cash.
    • Nuvve Holding Corp. (NASDAQ:NVVE) shares rose 60.3% to $0.73 in pre-market trading after the company launched Astrea AI forecasting for Nordic Energy market.
    • Surgalign Holdings, Inc. (NASDAQ:SRGA) shares gained 38% to $0.2781 in pre-market trading after gaining 6% on Thursday. Surgalign recently entered into an asset purchase agreement to sell its U.S. hardware and biomaterials assets and the equity interests in non-Debtor entities related to the Debtors' hardware business outside of the U.S. to Xtant Medical Holdings for $5 million.
    • VIQ Solutions Inc. (NASDAQ:VQS) shares climbed 23.3% to $0.38 in pre-market trading after gaining 4% on Thursday.
    • Lifetime Brands, Inc. (NASDAQ:LCUT) gained 21.2% to $5.59 in pre-market trading after adding around 5% on Thursday.
    • Trupanion, Inc. (NASDAQ:TRUP) gained 16.4% to $23.96 in pre-market trading after California and New York approved the company's requested rate increases.
    • Beneficient (NASDAQ:BENF) rose 12.1% to $4.37 in pre-market trading after dropping around 10% on Thursday.
    • Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) rose 12% to $0.7890 in pre-market trading after gaining 12% on Thursday.

    Losers

    • Spark Networks SE (NYSE:LOV) fell 32.1% to $0.5001 in pre-market trading. On June 21, Spark Networks got notice from Nasdaq Advising Co that Nasdaq has determined to deny the company’s request for continued listing on Nasdaq.
    • Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) fell 22.2% to $0.3550 in pre-market trading. Aeglea BioTherapeutics shares jumped 329% on Thursday after the company announced acquisition Of Spyre Therapeutics and concurrent oversubscribed $210M private investment positions.
    • Virgin Galactic Holdings, Inc. (NYSE:SPCE) shares fell 17.5% to $4.39 in pre-market trading. Virgin Galactic filed for mixed shelf.
    • ShiftPixy, Inc. (NASDAQ:PIXY) fell 16% to $1.68 in pre-market trading after surging over 51% on Thursday.
    • Biodexa Pharmaceuticals Plc (NASDAQ:BDRX) fell 15.8% to $0.0665 in pre-market. Biodexa Pharmaceuticals announced 1 ADR for 400 ordinary share ratio change effective July 5, 2023.
    • LumiraDx Limited (NASDAQ:LMDX) fell 11.6% to $0.4022 in pre-market trading. LumiraDx recently received UK approval for its COVID Ultra and COVID & RSV Tests.
    • Tempo Automation Holdings, Inc. (NASDAQ:TMPO) shares dropped 11.3% to $0.39 in pre-market trading. Tempo Automation shares jumped 20% on Thursday after the company announced it secured a $7 million convertible promissory note facility, strengthening its financial position and providing capital for the Optimum acquisition.
    • Singularity Future Technology Ltd. (NASDAQ:SGLY) fell 10.2% to $0.4803 in pre-market trading after gaining over 5% on Thursday.
    • Skillz Inc. (NYSE:SKLZ) fell 10% to $0.5382 in pre-market trading. Skillz announced a 1-for-20 reverse stock split, effective June 23, 2023.
    • Biofrontera Inc. (NASDAQ:BFRI) shares dropped 9.7% to $0.5122 in pre-market trading after declining around 4% on Thursday.

     

    Now Read This: Investor Sentiment Improves After Nasdaq Snaps 3-Session Losing Streak

    Get the next $AGLE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AGLE
    $BDRX
    $BENF
    $BFRI

    CompanyDatePrice TargetRatingAnalyst
    Lifetime Brands Inc.
    $LCUT
    2/13/2026$5.00Buy
    Roth Capital
    Lifetime Brands Inc.
    $LCUT
    1/26/2026$3.50Buy → Hold
    Canaccord Genuity
    Trupanion Inc.
    $TRUP
    8/13/2025$47.00Neutral
    Cantor Fitzgerald
    Virgin Galactic Holdings Inc.
    $SPCE
    6/30/2025$3.00Neutral
    Goldman
    Lifetime Brands Inc.
    $LCUT
    2/3/2025$11.50 → $6.75Buy → Neutral
    DA Davidson
    Trupanion Inc.
    $TRUP
    1/23/2025$57.00Neutral → Overweight
    Piper Sandler
    Trupanion Inc.
    $TRUP
    7/19/2024Outperform
    William Blair
    Trupanion Inc.
    $TRUP
    5/16/2024$35.00 → $49.00Neutral → Buy
    BofA Securities
    More analyst ratings

    $AGLE
    $BDRX
    $BENF
    $BFRI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Roth Capital initiated coverage on Lifetime Brands with a new price target

    Roth Capital initiated coverage of Lifetime Brands with a rating of Buy and set a new price target of $5.00

    2/13/26 9:51:55 AM ET
    $LCUT
    Industrial Machinery/Components
    Consumer Discretionary

    Lifetime Brands downgraded by Canaccord Genuity with a new price target

    Canaccord Genuity downgraded Lifetime Brands from Buy to Hold and set a new price target of $3.50

    1/26/26 10:01:23 AM ET
    $LCUT
    Industrial Machinery/Components
    Consumer Discretionary

    Cantor Fitzgerald initiated coverage on Trupanion with a new price target

    Cantor Fitzgerald initiated coverage of Trupanion with a rating of Neutral and set a new price target of $47.00

    8/13/25 8:15:02 AM ET
    $TRUP
    Medical Specialities
    Health Care

    $AGLE
    $BDRX
    $BENF
    $BFRI
    SEC Filings

    View All

    SEC Form 424B3 filed by Beneficient

    424B3 - Beneficient (0001775734) (Filer)

    2/18/26 6:05:49 AM ET
    $BENF
    Finance: Consumer Services
    Finance

    SEC Form SCHEDULE 13G filed by Biodexa Pharmaceuticals plc American Depositary Shs

    SCHEDULE 13G - Biodexa Pharmaceuticals Plc (0001643918) (Subject)

    2/17/26 9:55:22 PM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Beneficient

    10-Q - Beneficient (0001775734) (Filer)

    2/17/26 5:21:51 PM ET
    $BENF
    Finance: Consumer Services
    Finance

    $AGLE
    $BDRX
    $BENF
    $BFRI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Beneficient Reports Third Quarter Fiscal 2026 Results

    DALLAS, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Beneficient (NASDAQ:BENF) ("Ben" or the "Company"), a technology-enabled platform providing exit opportunities and primary capital solutions and related trust and custody services to holders of alternative assets, today reported its financial results for the fiscal 2026 third quarter, which ended December 31, 2025. Highlights of the quarter include: Resolved GWG Holdings, Inc. litigation and regained Nasdaq complianceGenerated $50 million in gross proceeds from asset salesFully paid off HH-BDH Credit Agreement principal balance (excluding $1.7 million for deferred interest and fees)Strengthened balance sheet and collateral base Commenting on the

    2/17/26 5:00:00 PM ET
    $BENF
    Finance: Consumer Services
    Finance

    Virgin Galactic Announces Date of Fourth Quarter and Full Year 2025 Financial Results and Conference Call

    Virgin Galactic Holdings, Inc. (NYSE:SPCE) ("Virgin Galactic" or the "Company") today announced that it will report its financial results for the fourth quarter and full year 2025 following the close of the U.S. markets on Monday, March 30, 2026. This date aligns with Securities and Exchange Commission rules requiring the Company, as a non-accelerated filer, to submit its annual report on Form 10-K within 90 days after the end of the fiscal year. Virgin Galactic will host a conference call to discuss the results that day at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time). A live webcast and replay of the conference call will be available on the Company's Investor Relations website at inve

    2/17/26 4:06:00 PM ET
    $SPCE
    Transportation Services
    Consumer Discretionary

    Biofrontera Inc. Announces Database Lock of Phase 1 Pharmacokinetics Study of Ameluz® for Actinic Keratoses on Trunk and Extremities

    Phase 1 maximal-use pharmacokinetics (PK) study completed in support of planned U.S. label expansionData to complement previously announced positive Phase 3 efficacy results on extremities, neck and trunkSupplemental NDA submission for extremities, neck and trunk indication expected in Q3 2026 WOBURN, Mass., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), today announced that the database of its Phase 1 PK study evaluating Ameluz® (aminolevulinic acid hydrochloride) topical gel for the treatment of mild to moderate actinic kera

    2/17/26 9:15:00 AM ET
    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGLE
    $BDRX
    $BENF
    $BFRI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Bearman Asher claimed ownership of 69,272 shares (SEC Form 3)

    3 - TRUPANION, INC. (0001371285) (Issuer)

    2/17/26 5:08:12 PM ET
    $TRUP
    Medical Specialities
    Health Care

    Chief Operating Officer Gallagher John R sold $13,618 worth of shares (430 units at $31.67), decreasing direct ownership by 1% to 31,861 units (SEC Form 4)

    4 - TRUPANION, INC. (0001371285) (Issuer)

    1/29/26 6:57:35 PM ET
    $TRUP
    Medical Specialities
    Health Care

    Director Low Murray B exercised 23,213 shares at a strike of $8.57, increasing direct ownership by 18% to 154,534 units (SEC Form 4)

    4 - TRUPANION, INC. (0001371285) (Issuer)

    1/12/26 8:44:15 PM ET
    $TRUP
    Medical Specialities
    Health Care

    $AGLE
    $BDRX
    $BENF
    $BFRI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and COO Smith Ted C. bought $20,606 worth of shares (7,155 units at $2.88), increasing direct ownership by 126% to 12,855 units (SEC Form 4)

    4 - Nuvve Holding Corp. (0001836875) (Issuer)

    12/23/24 5:09:54 PM ET
    $NVVE
    Electrical Products
    Industrials

    President and COO Smith Ted C. bought $10,802 worth of shares (3,928 units at $2.75), increasing direct ownership by 222% to 5,700 units (SEC Form 4)

    4 - Nuvve Holding Corp. (0001836875) (Issuer)

    12/20/24 5:24:40 PM ET
    $NVVE
    Electrical Products
    Industrials

    Director Cangany Peter T Jr bought $23,750 worth of shares (25,000 units at $0.95) (SEC Form 4)

    4 - Beneficient (0001775734) (Issuer)

    11/25/24 4:29:26 PM ET
    $BENF
    Finance: Consumer Services
    Finance

    $AGLE
    $BDRX
    $BENF
    $BFRI
    Leadership Updates

    Live Leadership Updates

    View All

    Appointment of Fiona Sharp to the Board as Chief Financial Officer and Company Secretary

    January 05, 2026 Biodexa Pharmaceuticals PLC Appointment of Fiona Sharp to the Board as Chief Financial Officer and Company Secretary Biodexa Pharmaceuticals PLC ("Biodexa" or "the Company"), (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, is delighted to announce the promotion of Fiona Sharp to Chief Financial Officer and Company Secretary along with her election to the Board of Directors of the Company with immediate effect. Ms Sharp is a senior finance professional having joined the Company as Group Financial Controller in December 2019. During her tenure, she has consistentl

    1/5/26 8:30:00 AM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Beneficient Appoints Peter T. Cangany Jr. as Chairman of the Board

    DALLAS, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Beneficient (NASDAQ:BENF) ("Ben" or the "Company"), a technology-enabled platform providing exit opportunities and primary capital solutions and related trust and custody services to holders of alternative assets, today announced that its Board of Directors (the "Board") has appointed Peter T. Cangany Jr. as Chairman of the Board, effective December 15, 2025. Mr. Cangany has served as a director of Beneficient and as Chairman of its independent Audit Committee since 2019. He brings decades of leadership experience in financial reporting, accounting, and corporate governance within the financial services industry. Mr. Cangany retired as a partner

    12/17/25 7:30:00 AM ET
    $BENF
    Finance: Consumer Services
    Finance

    Interim results for the six months ended June 30, 2025

    September 12, 2025 Biodexa Pharmaceuticals PLC("Biodexa" or the "Company") Interim results for the six months ended June 30, 2025 Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announces its unaudited interim results for the six months ended June 30, 2025 which will also be made available on the Company's website at www.biodexapharma.com. OPERATIONAL HIGHLIGHTS The Company announced the following in the six months ended June 30, 2025: Allowance by the US Patent and Trademark Office of patent application No. 17/391-495 "Oral Rapamycin Nanopart

    9/12/25 8:30:00 AM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGLE
    $BDRX
    $BENF
    $BFRI
    Financials

    Live finance-specific insights

    View All

    Beneficient Reports Third Quarter Fiscal 2026 Results

    DALLAS, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Beneficient (NASDAQ:BENF) ("Ben" or the "Company"), a technology-enabled platform providing exit opportunities and primary capital solutions and related trust and custody services to holders of alternative assets, today reported its financial results for the fiscal 2026 third quarter, which ended December 31, 2025. Highlights of the quarter include: Resolved GWG Holdings, Inc. litigation and regained Nasdaq complianceGenerated $50 million in gross proceeds from asset salesFully paid off HH-BDH Credit Agreement principal balance (excluding $1.7 million for deferred interest and fees)Strengthened balance sheet and collateral base Commenting on the

    2/17/26 5:00:00 PM ET
    $BENF
    Finance: Consumer Services
    Finance

    Virgin Galactic Announces Date of Fourth Quarter and Full Year 2025 Financial Results and Conference Call

    Virgin Galactic Holdings, Inc. (NYSE:SPCE) ("Virgin Galactic" or the "Company") today announced that it will report its financial results for the fourth quarter and full year 2025 following the close of the U.S. markets on Monday, March 30, 2026. This date aligns with Securities and Exchange Commission rules requiring the Company, as a non-accelerated filer, to submit its annual report on Form 10-K within 90 days after the end of the fiscal year. Virgin Galactic will host a conference call to discuss the results that day at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time). A live webcast and replay of the conference call will be available on the Company's Investor Relations website at inve

    2/17/26 4:06:00 PM ET
    $SPCE
    Transportation Services
    Consumer Discretionary

    Trupanion Reports Fourth Quarter & Full Year 2025 Results

    SEATTLE, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Trupanion, Inc. (NASDAQ:TRUP), a leading provider of medical insurance for cats and dogs, today announced financial results for the fourth quarter and full year ended December 31, 2025. "Since 2021, we've delivered more than $500 million in discretionary profit, growing at a 22% CAGR, including over $150 million last year alone," said Margi Tooth, Chief Executive Officer and President of Trupanion. "In 2025, we achieved our 15% annual margin target, while increasing subscription revenue and reinvesting record profits to drive four straight quarters of higher retention and accelerating gross pet adds. We're poised to advance confidently into our n

    2/12/26 4:05:00 PM ET
    $TRUP
    Medical Specialities
    Health Care

    $AGLE
    $BDRX
    $BENF
    $BFRI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Skillz Inc.

    SC 13D/A - Skillz Inc. (0001801661) (Subject)

    12/12/24 4:01:36 PM ET
    $SKLZ
    EDP Services
    Technology

    Amendment: SEC Form SC 13G/A filed by Biodexa Pharmaceuticals plc American Depositary Shs

    SC 13G/A - Biodexa Pharmaceuticals Plc (0001643918) (Subject)

    11/20/24 11:56:39 AM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Biodexa Pharmaceuticals plc American Depositary Shs

    SC 13G/A - Biodexa Pharmaceuticals Plc (0001643918) (Subject)

    11/14/24 5:12:47 PM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care